Acute Kidney Injury (AKI) is a sudden and severe decline in kidney function that can arise from various causes, often leading to serious complications. A key pathological mechanism contributing to AKI is oxidative stress, which damages kidney cells and impairs their ability to filter waste and maintain fluid balance. Effective strategies for renal protection & kidney health are desperately needed to improve patient outcomes.


At NINGBO INNO PHARMCHEM CO.,LTD., we are keenly interested in advanced therapeutic compounds that offer targeted solutions for conditions like AKI. Mitochondrial Peptide 31 emerges as a promising candidate due to its potent antioxidant activity and its specific affinity for mitochondria, the energy factories within kidney cells.


Mitochondrial Peptide 31 acts as a powerful acute kidney injury antioxidant peptide. By directly targeting mitochondria in renal cells, it works to prevent oxidative damage and dysfunction, which are critical factors in AKI progression. This peptide's ability to maintain mitochondrial integrity and function supports the kidney's natural healing processes and helps mitigate further injury. Its mechanism as a cardiolipin peroxidase inhibitor is vital for preserving the inner mitochondrial membrane, ensuring sustained cellular energy production necessary for healthy kidney function.


The therapeutic potential of Mitochondrial Peptide 31 extends to broader aspects of organ protection, making it a valuable subject in ongoing research for comprehensive kidney care. Its strong antioxidant capabilities make it an excellent candidate for improving renal resilience against various insults. As a dedicated supplier and manufacturer of high-quality chemical compounds, NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting advancements in kidney health. If your research or development requires a reliable source for Mitochondrial Peptide 31, we invite you to buy from us. We ensure the highest purity and can provide competitive price information to support your innovative projects aimed at protecting and restoring kidney function.


Mitochondrial Peptide 31 offers a significant step forward in the development of targeted therapies for AKI and other kidney-related conditions, representing new hope for improved renal outcomes.